Lindsey B. Cotton, Chief Strategy Officer at TensorBlack, shared on LinkedIn:
“A $10 premium increase doesn’t sound like much.
Until you remember that cancer care isn’t experienced one bill at a time. Affordability isn’t binary, it’s cumulative.
It’s experienced as the accumulation of premiums, copays, transportation, time away from work, caregiver expenses, and prescription costs.
Whether Medicare Part D premiums increase by $10 or $20 each month for some beneficiaries isn’t just a policy story.
It’s a reminder that affordability directly affects adherence and accessibility.
As more cancer therapies move from the infusion suite to the pharmacy counter, Medicare Part D has become increasingly important for oncology patients.
The biggest takeaway isn’t simply whether premiums rise.
It’s that this year’s Medicare Open Enrollment may be one of the most important in recent memory. Formularies, premiums, deductibles, and pharmacy networks can all change, and choosing the wrong plan can significantly increase out-of-pocket costs for patients taking high-cost medications.
This is where oncology financial navigators, pharmacists, and community oncology practices become indispensable.
Health policy doesn’t stop at Washington. It ultimately shows up in the exam room, at the pharmacy counter, and in the decisions patients make about whether they can afford to start (or continue) the treatments that could save their lives.
This is your signal to start Open Enrollment conversations now, not in October. Medication reviews, formulary checks, financial navigation referrals. The patients most at risk won’t tell you they’re struggling. They’ll just stop filling prescriptions.
Prevention applies to financial toxicity too.”
Other articles about Medicare Part D on OncoDaily.